University of Miami Bascom Palmer Eye Institute
Welcome,         Profile    Billing    Logout  
 4 Trials 
13 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lee, Wendy W
THRIVE, NCT05176639 / 2021-006794-37: A Safety, Tolerability and Efficacy Study of Veligrotug (VRDN 001) in Healthy Volunteers and Participants with Thyroid Eye Disease (TED) ( )

Active, not recruiting
3
154
Europe, Canada, US, RoW
Veligrotug (VRDN-001) Phase 1/2 MAD (HV and TED), VRDN-001 Phase 3 Cohort (THRIVE), VRDN-001 Placebo
Viridian Therapeutics, Inc., Viridian Therapeutics, Inc.
Thyroid Eye Disease
07/24
03/25
Wester, Sara
NCT05002998: TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study

Active, not recruiting
4
313
Europe, US
Teprotumumab, TEPEZZA, Placebo, Saline Solution
Amgen
Thyroid Eye Disease
04/26
04/26
Lam, Byron
IIH EVOLVE, NCT05347147 / 2021-006664-24: A Trial to Determine the Efficacy and Safety of Presendin in IIH

Terminated
3
14
Europe, US, RoW
Presendin, Placebo
Invex Therapeutics Ltd., Premier Research Group plc, University Hospitals Birmingham Neuro Ophthalmology Reading Centre, Birmingham, UK, Iowa Visual Field Reading Centre, Iowa, USA
Idiopathic Intracranial Hypertension
09/23
10/23
liMeliGhT, NCT06388200: A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa

Recruiting
3
150
US
Sub-Retinal Administration of OCU400-301
Ocugen
Retinitis Pigmentosa
06/25
10/26
TEASE, NCT02402660: Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease

Recruiting
2
140
US
ALK-001, C20-D3-Retinyl Acetate, C20 Deuterated vitamin A, Placebo
Alkeus Pharmaceuticals, Inc.
Stargardt Disease, Stargardt Macular Degeneration, Stargardt Macular Dystrophy, Autosomal Recessive Stargardt Disease 1 (ABCA4-related)
12/24
03/25
PRODYGY, NCT05748873: Promising ROd-cone DYstrophy Gene TherapY

Recruiting
1/2
33
Europe, US
SPVN06
SparingVision
Retinitis Pigmentosa
03/25
03/29
LIGHTHOUSE, NCT05878860: ATSN-201 Gene Therapy in RS1-Associated X-linked Retinoschisis

Recruiting
1/2
21
US
ATSN-201
Atsena Therapeutics Inc.
X-linked Retinoschisis
10/25
10/29
Platypus, NCT05902962: SAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects

Recruiting
1
20
US
VP-001
PYC Therapeutics
Retinal Dystrophy, PRPF31 Mutationassociated Retinal Dystrophy, RP11
05/24
05/24
NCT06140329: Natural History of Autosomal Dominant Optic Atrophy (ADOA), Caused by OPA1 Mutation

Recruiting
N/A
40
Europe, US, RoW
PYC Therapeutics
Autosomal Dominant Optic Atrophy, Optic Atrophy, Autosomal Dominant, Optic Atrophies, Hereditary, Kjer Optic Atrophy
03/26
06/26
POLARIS, NCT06435000: An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene

Recruiting
N/A
75
Europe, US
Splice Bio
Stargardt, Stargardt's Disease, Stargardt Disease, STGD1
12/26
02/27
Tran, Van ANn
ABNCoV2-03, NCT05329220 / 2021-005504-36: ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2

Completed
3
4223
Europe, US
ABNCoV2, Comirnaty
Bavarian Nordic
COVID-19 Disease
03/23
10/23
RSV OA=ADJ=012, NCT06534892: An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study

Recruiting
3
12000
Europe, Canada, Japan, US, RoW
RSVPreF3 OA vaccine
GlaxoSmithKline
Respiratory Syncytial Virus Infections
09/26
09/26
SWEET, NCT06214221: Using Signos mHealth Platform in Adults for Weight Management

Active, not recruiting
N/A
380
US
Signos System, Standard Lifestyle Education
Signos Inc, Lindus Health, Inc.
Overweight and Obesity, Metabolic Syndrome, Weight Loss
12/24
04/26
Shoji, Marissa
No trials found
Leveille, Lynn
No trials found

Download Options